


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A C-Glycosylisoflavone compound of the formula (I) having alkylaminoalkoxyl substituent or a pharmaceutically acceptable salt thereof:



wherein, R₁ and R₂ are independently selected from hydrogen, (C₁-C₁₂) linear or branched alkylamino, mono- or di-(C₃₋₈)cycloalkylamino-C₁₋₆alkyl, or (C₅-C₁₄)heterocyclic-(C₁-C₆)alkyl; R₃ is selected from hydrogen, (C₁-C₁₂) linear or branched acyl, or C₆₋₁₄ aryl carbonyl; wherein R₁ and R₂ do not represent hydrogen simultaneously; the 1-position of D-glucosyl is connected with the 8-position of the isoflavone in a form of β-configured C-glycoside.

2. (Original) The compound according to claim 1, characterized in that in formula (2), R_1 and R_2 are independently selected from hydrogen, dimethylaminoethyl, diethylaminoethyl, di(n-propyl)aminoethyl, di(iso-propyl)aminoethyl, di(n-butyl)aminoethyl, di(iso-butyl)aminoethyl, di(tert-butyl)aminoethyl, pyrrolidinylethyl, piperidylethyl, morpholinylethyl, piperazinylethyl, N-methylpiperazinylethyl, N-ethylpiperazinylethyl, tert-butylaminoethyl, dicyclohexylaminoethyl, dimethylaminopropyl, diethylaminopropyl, di(n-propyl)aminopropyl, di(iso-propyl)aminopropyl, di(n-butyl)aminopropyl, di(iso-butyl)aminopropyl, di(tert-butyl)aminopropyl, pyrrolidinylpropyl, piperidylpropyl, morpholinylpropyl, piperazinylpropyl, N-methylpiperazinylpropyl, N-ethylpiperazinylpropyl, tert-butylaminopropyl, dicyclohexylaminopropyl, dimethylaminobutyl, diethylaminobutyl, di(n-propyl)aminobutyl, di(iso-propyl)aminobutyl, di(n-butyl)aminobutyl, di(iso-butyl)aminobutyl, di(tert-butyl)aminobutyl, pyrrolidinylbutyl, piperidylbutyl, morpholinylbutyl, piperazinylbutyl, N-methylpiperazinylbutyl, N-ethylpiperazinylbutyl, tert-butylaminobutyl, dicyclohexylaminobutyl, wherein R_1 and R_2 do not represent hydrogen simultaneously; R_3 is selected from hydrogen, propionyl, butyryl, isobutyryl, 2-methylbutyryl, 3-methylbutyryl, 2,2-dimethylpropionyl, valeryl, caproyl, heptanoyl, octanoyl, nonanoyl, decanoyl, lauroyl; or a pharmaceutically acceptable salt selected from the salts of hydrochloric acid, hydrobromic acid, phosphoric acid, phosphorous acid, sulfuric acid, methane sulfonic acid, p-toluene sulfonic acid, maleic acid, fumaric acid, tartaric acid, and various natural or non-natural amino acids.

3. (Currently amended) The compound according to claim 1-~~or 2~~, wherein the compound of the formula (I) is selected from:

4'-(3-N-piperidylpropoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone,
4'-(3-N-morpholinylpropoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone,
4'-(3-N-pyrrolidinylpropoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone,
4'-(3-diethylaminopropoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone,
4'-[3-di(n-propyl)aminopropoxy]-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone,
4'-[3-di(n-butyl)aminopropoxy]-7-hydroxy-8- β -D-(1-deoxyglucosyl)

Docket No.: 56860/C306
Amdt date January 3, 2006

isoflavone,

4'-[3-(4-methylpiperazinyl)propoxy]-7-hydroxy-8-β-D-(1-deoxyglucosyl)

isoflavone,

4'-[3-(4-ethylpiperazinyl)propoxy]-7-hydroxy-8-β-D-(1-deoxyglucosyl)

isoflavone,

4'-(4-N-piperidylbutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone,

4'-(4-N-morpholinylbutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone,

4'-(4-N-pyrrolidinylbutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone,

4'-(4-diethylaminobutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone,

4'-(4-di(n-propyl)aminobutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)- isoflavone,

4'-(4-di(n-butyl)aminobutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)

isoflavone,

4'-[4-(4-methylpiperazinyl)butoxy]-7-hydroxy-8-β-D-(1-deoxyglucosyl)

isoflavone,

4'-[4-(4-ethylpiperazinyl)butoxy]-7-hydroxy-8-β-D-(1-deoxyglucosyl)

isoflavone,

or a pharmaceutically acceptable salt thereof.

4. (Currently amended) A pharmaceutical composition comprising a compound of ~~any one of claims 1 to 3~~ claim 1 and a pharmaceutically acceptable carrier.

5. (Currently amended) A preparation method of a compound of ~~any one of claims 1 to 3~~ claim 1, characterized in comprising, reacting puerarin material with a suitable bis-functional group substituted compound such as a bihalogenated hydrocarbon, an alkylene bissulfonate, or a halogenated hydrocarbon monosulfonate etc., in a suitable solvent selected from water, acetone, dimethylformamide, dimethyl sulfoxide, and lower alcohols, under the presence of a base, an ambient to reflux- temperature, which is firstly mono-etherified followed by amination and/or salt-formation, to give the corresponding alkylaminoalkoxyl-substituted C-Glycosylisoflavone compound or a pharmaceutically acceptable salt thereof.

Docket No.: 56860/C306
Amdt date January 3, 2006

6. (Currently amended) Use of a compound of ~~any one of claims 1 to 3~~ claim 1 in the manufacture of a medicament for the treatment of cardio- and cerebrovascular diseases as well as a medicament for the treatment of hypoxia or ischemia.
7. (Currently amended) Use of a compound of ~~any one of claims 1 to 3~~ claim 1 in the manufacture of a medicament for the treatment of diabetes as well as diabetic complications.
8. (Currently amended) Use of a compound of ~~any one of claims 1 to 3~~ claim 1 in the manufacture of a medicament for the treatment of chemical poisoning, particularly alcoholism.